PharmaShots | Incisive News in 3 Shots

Subscribe Now

Cataplexy

Jazz Reports Results of Xywav (calcium- magnesium- potassium- and sodium oxybates) in P-III Study for Cataplexy or EDS in Patients with Narcolepsy

Jazz Reports Results of Xywav (calcium- magnesium- potassium- and sodium oxybates) in P-III Study for Cataplexy or EDS in Patients...

October 21, 2020

Jazz Pharmaceuticals' Xywav (calcium- magnesium- potassium- and sodium oxybates) Receives the US FDA's Approval for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy

Jazz Pharmaceuticals' Xywav (calcium- magnesium- potassium- and sodium oxybates) Receives the US FDA's Approval for Cataplexy or E...

July 22, 2020

Jazz Reports Results of JZP-258 in a P-III Study to Treat Cataplexy and Excessive Daytime Sleepiness in Patients with Narcolepsy

Jazz Reports Results of JZP-258 in a P-III Study to Treat Cataplexy and Excessive Daytime Sleepiness in Patients with Narcolepsy

September 26, 2019

Jazz Pharmaceuticals Reports Results of JZP-258 in P-III Study for Narcolepsy Patients with Cataplexy and Excessive Daytime Sleepiness

Jazz Pharmaceuticals Reports Results of JZP-258 in P-III Study for Narcolepsy Patients with Cataplexy and Excessive Daytime Sleepi...

March 27, 2019

Jazz Receives FDA Approval for Xyrem's (sodium oxybate) sNDA to Treat Cataplexy or Excessive Daytime Sleepiness in Pediatric Patients with Narcolepsy

Jazz Receives FDA Approval for Xyrem's (sodium oxybate) sNDA to Treat Cataplexy or Excessive Daytime Sleepiness in Pediatric Patie...

October 30, 2018

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us